Recommendation on the Nomenclature for
On behalf of the Control of Anticoagulation Subcommittee of
the SSC of the ISTH
Geoffrey D Barnes, Walter Ageno, Jack Ansell, Scott Kaatz
Scope and methodology Oral anticoagulants are used to prevent and treat a wide range of thromboembolic diseases.
Currently available oral anticoagulants include the vitamin K antagonists (VKA), such as warfarin. VKAs reduce the synthesis of functional vitamin K-dependent factors (II, VII, IX, X as well as protein C and protein S) by interfering in the vitamin K redox cycle.
The newer oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban) each directly inhibit an activated clotting factor, either IIa or Xa.
Their pharmacokinetic and pharmacodynamic properties are more predictable than the VKAs and therefore do not require routine monitoring of anticoagulant effect.